Author: openjargon

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in the spotlight after the FDA accepted its New Drug Application for TLX101-Px (Pixclara®), a PET imaging agent for glioma. TLX101-Px has received Orphan Drug and Fast Track status, with a key regulatory decision expected by September.

What did Telix Pharmaceuticals report?

• The US FDA accepted Telix’s NDA for TLX101-Px (Pixclara®), a PET agent for imaging brain cancer (glioma)
• The Prescription Drug User Fee Act (PDUFA) goal date is 11 September 2026
• TLX101-Px holds Orphan Drug and Fast Track designations in the US
• No FY 2026 revenue guidance has been assigned to TLX101-Px pending approval
• TLX101-Px aimed at addressing an unmet medical need in both adult and paediatric glioma cases

What else do investors need to know?

The FDA’s acceptance of the Telix NDA marks a key step toward potential commercialisation of TLX101-Px in the United States. This diagnostic agent aims to improve the differentiation between recurrent glioma and treatment-related changes, a persistent challenge in neuro-oncology.

TLX101-Px is expected to complement Telix’s broader LAT1-targeting therapeutic pipeline, notably the TLX101-Tx therapy under investigation in the IPAX-BrIGHT clinical trial. There are currently no marketing authorisations for TLX101-Px or TLX101-Tx in any region.

Telix has reaffirmed that FY 2026 guidance does not anticipate revenue for TLX101-Px, pending the FDA decision. The product could provide both clinical impact and financial upside if approved in the future.

What’s next for Telix Pharmaceuticals?

Investors can expect further updates as Telix works with the FDA ahead of the September 2026 goal date for TLX101-Px. The company is also advancing late-stage trials for related therapies, aiming to build a broader radiopharmaceutical portfolio for oncology and rare diseases.

Looking ahead, a successful approval could see Telix expand its presence in the US diagnostics market while pursuing commercial opportunities for both imaging and therapeutic candidates.

Telix Pharmaceuticals share price snapshot

Over the past year, Telix Pharmaceuticals shares have declined 49%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 16% over the same period.

View Original Announcement

The post Telix Pharmaceuticals: FDA accepts Pixclara NDA appeared first on The Motley Fool Australia.

More reading

• Where is the value amongst ASX healthcare shares?
• Monadelphous wins $145m of new and renewed resources sector contracts
• Fortescue accelerates world’s first large-scale industrial green energy grid
• 7 ASX 200 shares just upgraded to strong buy ratings
• 5 things to watch on the ASX 200 on Friday

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

I think putting money to work in the share market is always a good idea.

Regardless of the amount, what matters most is choosing businesses with strong long-term potential and building the habit of investing consistently.

The good news is that the Australian share market is home to many businesses that tick these boxes in 2026.

So, if I had $2,000 to invest today, these are three ASX shares I would consider buying in April.

Breville Group Ltd (ASX: BRG)

Breville is a business I think is often underestimated. It operates in premium kitchen appliances, but what stands out to me is how it has built a global brand. Its products are sold across multiple regions, and it continues to expand into new markets.

What I like is the combination of product innovation and international growth. The company has shown it can introduce new products that resonate with consumers while also scaling its distribution globally.

That gives it multiple avenues for growth over time.

Xero Ltd (ASX: XRO)

Xero offers exposure to software and digital transformation. The company provides accounting software to small and medium-sized businesses, and that shift toward cloud-based solutions is still ongoing.

The share price has been under pressure, partly due to concerns around competition and artificial intelligence (AI). But I think the long-term opportunity remains intact.

Xero has built a strong ecosystem and continues to grow its subscriber base, which supports recurring revenue. For me, it is a business that could continue compounding if it executes well.

Pro Medicus Ltd (ASX: PME)

Pro Medicus is one of the more impressive growth stories on the ASX. It operates in the medical imaging software market, providing solutions to hospitals and healthcare providers worldwide.

What stands out is the quality of the business. High margins, strong cash flow, and a growing list of major contracts all point to a company that is scaling effectively.

Healthcare demand is also supported by long-term trends, which give it a favourable backdrop.

Its valuation can look demanding at times, but I think that reflects the strength of the business and its positive long-term growth outlook.

Foolish Takeaway

A $2,000 investment can be the start of something meaningful.

Breville offers global consumer growth, Xero provides exposure to software and recurring revenue, and Pro Medicus brings high-quality healthcare growth.

Importantly, all three have the potential to grow over time, and that is what matters most to me when putting money to work.

The post $2,000 to invest? 3 ASX shares to consider today appeared first on The Motley Fool Australia.

More reading

• 7 ASX 200 shares just upgraded to strong buy ratings
• 3 reasons to buy Xero shares now
• 2 ASX 200 shares I rate as top buys for growth
• I’m following Warren Buffett to snap up these cheap ASX stocks
• 3 ASX shares tipped to grow 100% or more in the next 12 months

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

ASX healthcare stock EBR Systems Inc (ASX: EBR) is under the spotlight today after a new announcement sent the stock price surging on Thursday.

EBR is a clinical stage company that has developed its patented Wireless Stimulation Endocardially (WiSE) technology for the treatment of cardiac rhythm disease and to eliminate the need for cardiac pacing leads when delivering cardiac resynchronisation therapy. 

The healthcare stock rose roughly 7% yesterday after the company released an announcement to the ASX.

What did EBR systems announce?

Yesterday, the ASX healthcare stock released a preliminary version of its operating metrics earlier than scheduled by its quarterly reporting time frame (mid-May). 

According to Bell Potter, it is no surprise EBR has provided an early release as it gears up toward an eventual and large capital raising.

In yesterday’s report, the company said it saw strong Q1 2026 growth in commercial cases. 

It reported: 

• Robust commercial momentum continued through Q1 2026 with case volumes more than doubling from Q4 2025
• The WiSE® System was successfully implanted in 41 commercial patients during the quarter, bringing total
• implants across the pilot phase and Limited Market Release to 71
• EBR expects to report revenue in the range of US$2.25M to US$2.36M for Q1 2026, based on preliminary unaudited quarter-end results and subject to quarter-end closing adjustments. 

John McCutcheon, EBR Systems’ President & Chief Executive Officer said: 

In Q1 2026, we made impressive progress across both our commercial and clinical programs. Case volumes increased strongly during the quarter, reflecting growing physician experience, expanding site readiness and the steady execution of our Limited Market Release. We also continued to advance important clinical initiatives, with further enrolment in both the WiSE-UP post-approval study and the TLC-AU feasibility study, helping to expand the body of evidence supporting the WiSE System across a broader patient population. We are encouraged by the momentum we are seeing and remain focused on disciplined execution, physician training, site activation and building the clinical and commercial foundation for broader adoption of the WiSE System.

What did Bell Potter have to say?

Following the release, the team at Bell Potter released updated guidance on the ASX healthcare stock. 

The broker said the data continues to impress, with implants more than doubling to quarter of quarter to 41.

The success in implant volume is supported by the growing breadth of physicians trained and hospital contracts signed. A further 22 Physicians trained on the WiSE pacing system and 16 hospital contracts signed in the quarter, bringing the cumulative totals to 55 & 37. EBR appear be tracking well toward our hospital target of 60 for FY26.

Big upside for this ASX healthcare stock

Bell Potter has maintained its buy recommendation for EBR Systems, along with a price target of $2.00. 

From yesterday’s closing price of $0.68, that indicates a potential upside of 194%. 

It is not surprising that the market has reacted well to the data release, and with each data release we grow more confident in EBR’s commercial prospects and expect the market to do so as well.

The post Bell Potter says this ASX healthcare stock could rise nearly 200% appeared first on The Motley Fool Australia.

More reading

• Why Bendigo Bank, EBR Systems, Strickland, and Woodside shares are rising today
• Experts name 2 ASX financials stocks to watch closely
• 3 ASX penny stocks drawing positive ratings from experts
• Guess which ASX stock could more than triple in value according to Morgans!
• Is now the time to jump on these ASX real estate stocks?

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares in Treasury Wine Estates Ltd (ASX: TWE) just can’t catch a break.

The wine giant behind premium brands like Penfolds slipped another 1% on Thursday and is now down roughly 25% year to date and a staggering 53% over the past 12 months. Unfortunately, this kind of underperformance isn’t new for long-suffering shareholders.

So, is the ASX wine stock a hidden gem emerging or a classic value trap?

What’s been going on?

Treasury Wine shares have been battling a cocktail of challenges.

From shifting global demand to premiumisation risks and supply chain pressures, the business has struggled to regain investor confidence. But one issue is drawing particular scrutiny right now: inventory.

Broker Ord Minnett recently highlighted concerns around tight grape supply contracts in both the US and Australia. These agreements are expected to keep inventory levels elevated for longer than previously anticipated.

According to the broker:

Combined, the impact of these contract terms means Ord Minnett estimates Treasury’s inventory will increase again in FY27 before scaling down in the following years.

Size-wise, we see inventory topping out at circa $2.9 billion, a whisker away from the company’s current market capitalisation and twice the inventory size it held a decade ago.

Big red flag

That’s a big red flag for this blue chip. High inventory levels can tie up capital, pressure margins, and signal weaker-than-expected demand.

In response, Ord Minnett has increased its debt assumptions and trimmed its price target from $5.00 to $4.50. It also upgraded its recommendation, but only to hold from lighten. The broker noted the sharp recent selloff of Treasury Wine shares, including an 18% slide in March and close to a 25% drop year to date.

Even at the reduced target, that implies only around 14% upside from current levels.

Analyst snapshot: cautious at best

Ord Minnett’s view isn’t an outlier. Across the market, most brokers are sitting on the fence. The consensus rating on Treasury Wine shares is broadly a hold, reflecting a balance between long-term brand strength and near-term uncertainty.

The average price target sits around $5.24, suggesting potential upside of roughly 33%. That may sound appealing, but it also highlights the lack of conviction. This isn’t a stock analysts are rushing to back aggressively.

Foolish Takeaway

There’s no denying Treasury Wine owns a portfolio of premium brands and has global reach. Those strengths could pay off over time.

But right now, the risks are hard to ignore. Elevated inventory, rising debt assumptions, and patchy demand trends are weighing on sentiment. And while the share price fall is eye-catching, it hasn’t yet triggered widespread bullishness among brokers.

For investors, that puts Treasury Wine shares in a tricky middle ground. It might offer value, but it’s far from a clear-cut bargain.

The post Down 53%, are Treasury Wine shares a true gem or a value trap? appeared first on The Motley Fool Australia.

More reading

• Buy, hold, or sell? Treasury Wine, Domino’s Pizza, and Telstra shares
• These are the 10 most shorted ASX shares
• Treasury Wine shares hit 10-year lows last week. So why are buyers stepping in now?
• These are the 10 most shorted ASX shares
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Treasury Wine Estates. The Motley Fool Australia has positions in and has recommended Treasury Wine Estates. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Index (ASX: XJO) shares fell 7.8% in March after the US and Israel attacked Iran, triggering a global oil shock.

Oil and gas prices soared while gold and other metals crumbled, impacting ASX 200 shares in different ways.

Shares in the energy sector surged 18.5% while the materials sector, which includes Australia’s biggest miners, crumbled 14.1%.

Amid the upheaval for share prices, brokers reviewed their ratings and 12-month targets on a bunch of ASX stocks.

Here are some of the ASX 200 shares elevated to strong buy consensus status after last month’s turmoil.

7 ASX 200 shares newly elevated to strong buy ratings

These ASX shares have just been upgraded to strong buy consensus ratings on the CommSec platform.

A consensus rating represents the average rating among analysts.

Genesis Minerals Ltd (ASX: GMD)

The Genesis Minerals share price dropped 20.7% in March alongside a steep fall in the gold price.

So far this month, the ASX 200 gold mining share is up 10.9% to $6.53 at yesterday’s close.

MA Financial is among the brokers that have upgraded Genesis Minerals to a buy rating.

The broker has lifted its 12-month price target from $8.05 to $8.40.

Orica Ltd (ASX: ORI)

The Orica share price descended 17.9% in March.

So far this month, the ASX materials share is up 6.7% to $21.40.

Jefferies has reiterated its buy recommendation, but reduced its price target from $25.73 to $24.04.

Qantas Airways Ltd (ASX: QAN)

The Qantas share price fell 15.9% in March.

So far in April, the ASX 200 airline share has rebounded 8.6% to $9.09.

Jefferies has reiterated its buy rating with a price target of $12.80.

WiseTech Global Ltd (ASX: WTC)

The WiseTech Global share price declined 20% in March.

So far in April, the market’s largest ASX 200 tech share is up just 1.6% to $38.62.

Morgan Stanley is buy-rated on Wisetech but has slashed its target from $100 to $70.

Xero Ltd (ASX: XRO)

The Xero share price descended 9.7% in March.

The tech share has fallen a further 2.3% in April to $73.41 at yesterday’s close.

Morgan Stanley has reiterated its buy recommendation with a $130 target.

Yancoal Australia Ltd (ASX: YAL)

The Yancoal share price skyrocketed 41.5% in March, as power plants switched from gas to coal.

So far this month, the ASX 200 coal share has declined 10.3%.

Huatai Securities is buy-rated on Yancoal with a $14.40 share price target.

CAR Group Ltd (ASX: CAR)

The CAR Group share price fell 14% in March.

In April, the ASX 200 retail share is up 2.7% to $23.41.

Morgan Stanley reiterated its buy recommendation last week.

However, the broker reduced its 12-month target from $38 to $32.

The post 7 ASX 200 shares just upgraded to strong buy ratings appeared first on The Motley Fool Australia.

More reading

• 3 reasons to buy Xero shares now
• 5 things to watch on the ASX 200 on Friday
• ASX 200 energy shares whipsaw amid fragile ceasefire
• Why Orora, Select Harvests, Tamboran, and WiseTech shares are sinking today
• Orora updates FY26 outlook as Saverglass earnings take a hit

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended WiseTech Global and Xero. The Motley Fool Australia has positions in and has recommended WiseTech Global and Xero. The Motley Fool Australia has recommended CAR Group Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

It hasn’t been a great stretch for some of the market’s highest-quality ASX stocks, but savvy investors know that pullbacks can be where the real opportunities are found.

Two standout ASX stocks — REA Group Ltd (ASX: REA) and Aristocrat Leisure Ltd (ASX: ALL) — were among the losers again on Thursday. In fact, both have shed roughly 30% of their value over the past six months.

While that might rattle short-term traders, brokers are increasingly viewing this weakness as a compelling long-term entry point.

REA Group

When it comes to dominant digital platforms, REA Group remains one of the ASX’s crown jewels.

The ASX stock sits at the heart of Australia’s online property advertising market through its flagship realestate.com.au platform, giving it powerful pricing power and a highly scalable business model.

While the housing cycle can create short-term volatility, REA’s long-term growth story remains intact. It’s supported by premium listings, depth products, and international expansion.

The recent price weakness on the ASX stock appears to have caught the attention of analysts. Broker Morgan Stanley currently has an overweight rating on REA’s shares, alongside a $230.00 price target. That implies a potential upside of roughly 44% over the next 12 months.

For long-term investors, that’s a strong vote of confidence in both the company’s fundamentals and its ability to rebound as market conditions stabilise.

Aristocrat Leisure

Gaming technology leader Aristocrat Leisure is another high-quality name that has fallen out of favour recently. And the ASX stock could be primed for a comeback.

Aristocrat generates the bulk of its earnings from gaming machines and digital content, particularly in the lucrative US market. While sentiment has softened in recent months, underlying demand trends appear far more resilient than the share price suggests.

In fact, analysts are seeing encouraging signs. The team at Macquarie Group Ltd (ASX: MQG) has retained its outperform rating on the ASX stock, and set a $63.00 price target. That represents potential upside of approximately 33% from current levels.

Macquarie has been reviewing recent US casino gaming data and noted year-on-year growth, a positive signal for Aristocrat’s core land-based gaming business. Combined with its expanding digital segment, the company appears well placed to deliver long-term earnings growth.

Foolish Takeaway

Market pullbacks can be uncomfortable, but they often create rare opportunities to buy high-quality ASX stocks at discounted prices.

With both REA Group and Aristocrat Leisure down significantly and backed by bullish broker forecasts, long-term investors may want to take a closer look before the market sentiment turns.

The post 2 high-quality ASX stocks to buy and hold long term appeared first on The Motley Fool Australia.

More reading

• 3 fantastic ASX shares that could help build long-term wealth
• 3 of the best ASX retirement shares to buy now
• How to invest $1,000 per month in ASX shares and build long-term wealth
• 3 ASX 200 shares that could quietly compound for years
• Morgans names two ASX 200 shares to buy and one to sell this week

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

CSL Ltd (ASX: CSL) shares finished the day 1.37% lower when the ASX closed on Thursday afternoon, at $140.23 per share.

The decline is part of a long and consistent tumble for Australian biotech stock over the past 18 months.

The share price is now 40% lower than 12 months ago, and down 18.5% for the year-to-date.

It’s not all bad news out of the biotech giant though. Here are three reasons to add the shares to your portfolio, and three reasons to sell up.

3 reasons to buy CSL shares

1. It looks like headwinds are easing

CSL has faced huge headwinds over the past 18 months. From uninspiring financial results, to a revenue and growth profit guidance downgrade, a surprise restructure announcement, and even a shock CEO exit, several events have spooked investors and sent the company’s share price south. But I think these headwinds are finally easing and that downward pressure on CSL shares will soon lift.

2. There’s a huge demand for CSL products

At the core of its CSL’s business are its plasma-derived medicines, including immunoglobulins, albumin, and clotting factors. In fact, its blood plasma division dominates the market for rare blood disorders and immunoglobulin products. Global demand for plasma therapies is strong and growing too, and CSL is well-placed to absorb plenty of the upcoming demand.

3. Analysts tip a huge upside

Analysts are very bullish on the outlook for CSL shares. TradingView data shows 12 out of 28 analysts have a buy or strong buy rating on the stock with an upside of up to 91.6% to $286.67 per share over the next 12 months.

3 reasons to sell CSL shares

1. The market has fallen out of love with CSL shares

CSL was once widely viewed as one of the most dependable growth companies on the ASX. But over the past few years it has experienced a notable slowdown in earnings growth and a sharp share price reduction. Investors are concerned that there isn’t enough concrete proof that company and share price growth can return.

2. A sector-wide rotation makes healthcare shares less attractive

ASX healthcare shares have lagged behind most other sectors on the index so far in 2026 as investors reposition themselves towards ASX energy stocks, resources, and defensive assets. This has seen a broad rotation away from healthcare stocks like CSL while geopolitical instability continues to rattle markets. It doesn’t look like this will change any time in the near future. 

3. CSL’s growth outlook has slowed

CSL cut its FY26 revenue growth forecast to 2-3%, down from 4-5% previously at its AGM in October last year. It also downgraded its profit growth for FY26 to 4-7%, down from 7-10% previously. The company also revised its medium-term outlook for fiscal years 2027 and 2028, reducing expected NPAT growth from low-teens to high-single digits, well below the double-digit expansion rates it had previously experienced. 

Not only has CSL’s growth outlook slowed significantly, it happened very soon after the initial guidance figures were released, suggesting that either it is (or will) face some significant headwinds or management simply overestimated growth potential. 

The post CSL shares: 3 reasons to buy and 3 reasons to sell appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: CSL, Magellan, and Woodside shares
• What’s Bell Potter’s updated view on CSL shares?
• Why are CSL shares struggling to regain momentum?
• 5 things to watch on the ASX 200 on Thursday
• How to invest $1,000 per month in ASX shares and build long-term wealth

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Now could be the time to buy Life360 Inc (ASX: 360) shares for big potential returns.

That’s the view of analysts at Bell Potter, who remain bullish on the family safety technology company.

What is the broker saying?

Bell Potter believes there is a chance that Life360 will be forced to downgrade its bold monthly active user (MAU) guidance for 2026. It said:

We have reviewed our Life360 forecasts and the key change we have made is to lower our forecast growth in global MAUs this year from 19.2% to 17.5%. The significance of this change is that the guidance is 20% growth and, while we were already marginally below this level before, we are now more significantly below and this suggests or implies we see potential for a downgrade to this metric in the guidance at some stage.

The trigger for making this change is we have reduced our forecast growth for global MAUs in Q1 from 18.8% to 17.6% to be more consistent with the guidance of <20% growth. This level of forecast growth in Q1 makes it look difficult for the full year guidance to be achieved and, for instance, requires that global MAUs increase by >5m in each of Q2, Q3, and Q4 versus our forecast of 2.6m in Q1.

However, despite lowering its MAU expectations, the broker has not made a change to its revenue or earnings estimates. That’s because it believes Life360 can convert more existing users to paid plans than previously estimated. It adds:

Despite the lowering in our global MAU growth forecast in 2026 there is no change in our revenue or earnings forecasts as, on the flip side, we have increased our conversion rate forecasts so that there is no change in our paying circle forecast for the full year.

Our average forecast quarterly conversion rate – measured in crude or broad terms – has increased from 3.4% to 3.5% which is still below the average 3.6% in 2025. We are therefore still modestly below last year’s level which is perhaps conservative given the addition of Pet GPS but there was an unusual spike in the conversion rate in 3Q2025 which we assume is not repeated this year.

Big potential returns for Life360 shares

According to the note, the broker has retained its buy rating on Life360 shares with a trimmed price target of $35.50 (from $37.75).

Based on its current share price of $20.14, this implies potential upside of approximately 75% for investors over the next 12 months.

The broker concludes:

We have reduced the multiple we apply in the EV/EBITDA valuation from 37.5x to 35x and increased the WACC we apply in the DCF from 9.2% to 9.5% given the risk we see of a potential downgrade to the global MAU growth guidance for this year.

We stress, however, that we see less risk of a downgrade to the revenue or adjusted EBITDA guidance given we believe any shortfall in MAU growth can be made up by a higher conversion rate. The net result is a 6% reduction in our target price to $35.50 which is still a significant premium to the share price so we maintain our BUY recommendation.

The post Here’s why Life360 shares could rise a massive 75% appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Friday
• 3 ASX shares that could double over the next decade (or much sooner)
• Why Arafura Rare Earths, Eagers Automotive, Life360, and Pro Medicus shares are racing higher today
• Why are ASX 200 tech stocks like WiseTech and Life360 going gangbusters on Wednesday?
• Is now the perfect time to buy ASX growth shares?

Motley Fool contributor James Mickleboro has positions in Life360. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360. The Motley Fool Australia has positions in and has recommended Life360. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Xero Ltd (ASX: XRO) shares have had a tough run over the past 12 months.

During this time, the cloud accounting platform provider’s shares have fallen over 60% from their high as investors grapple with rising interest rates and concerns around artificial intelligence (AI) disruption.

But for long-term investors, could this be a buying opportunity? Let’s look at three reasons why it could be.

A significant reset in valuation for Xero shares

The first reason to consider Xero shares is the sharp decline itself.

High-quality growth companies can fall out of favour quickly when sentiment shifts. In Xero’s case, fears that AI could disrupt traditional accounting software have weighed heavily on the stock.

However, while AI may change how accounting is done, it is unlikely to remove the need for trusted platforms that manage financial data, compliance, and workflows.

With the share price having reset materially, investors are now able to access Xero shares at a far more reasonable valuation than in previous years.

Turning AI from a threat into an opportunity

Another reason to be positive on Xero is how it is responding to AI disruption.

Rather than being left behind, Xero is leaning into the technology through its partnership with AI giant Anthropic.

The deal means Xero users will be able to work with their financial data directly inside a major AI platform and provides a new way for Claude to power end-to-end financial workflows for small businesses at scale.

Xero highlighted that for millions of small businesses, this will mean less time manually chasing invoices or piecing together cash flow across multiple reports, with Claude proactively surfacing the insights and actions that would otherwise take hours to find.

In this context, AI becomes less of a threat and more of a feature. If executed well, it could strengthen Xero’s value proposition and deepen its competitive advantage.

A platform with room to grow

A third reason to consider Xero shares is the strength and scalability of its platform.

Xero has built a global ecosystem connecting small businesses, accountants, and third-party applications. Once embedded, switching becomes difficult due to the integration of financial data and workflows.

Looking ahead, growth is not just about adding new users. There is a significant opportunity to increase revenue per user through additional services such as payments, payroll, and financial tools.

By expanding what it offers within its existing base, Xero can continue growing even without rapid subscriber gains.

Overall, for investors willing to look beyond short-term concerns, Xero’s reset valuation, proactive AI strategy, and scalable platform could make it a compelling opportunity right now.

The post 3 reasons to buy Xero shares now appeared first on The Motley Fool Australia.

More reading

• I’m following Warren Buffett to snap up these cheap ASX stocks
• 3 ASX shares tipped to grow 100% or more in the next 12 months
• Down 35% in 2026, are Xero shares the bargain buy of April?
• Brokers rate these 3 top ASX shares as buys in April
• Forget Easter eggs, these ASX shares could be your best buys this month

Motley Fool contributor James Mickleboro has positions in Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Xero. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

On Thursday, the S&P/ASX 200 Index (ASX: XJO) continued its positive run and pushed higher. The benchmark index rose 0.25% to 8,973.2 points.

Will the market be able to build on this on Friday and end the week on a high? Here are five things to watch:

ASX 200 expected to edge lower

The Australian share market looks set to edge lower on Friday despite a decent night in the United States. According to the latest SPI futures, the ASX 200 is expected to open 5 points lower this morning. On Wall Street, the Dow Jones was up 0.6%, the S&P 500 rose 0.6% and the Nasdaq climbed 0.8%.

Oil prices rebound

It could be a good finish to the week for ASX 200 energy shares such as Santos Ltd (ASX: STO) and Woodside Energy Group Ltd (ASX: WDS) after oil prices rebounded overnight. According to Bloomberg, the WTI crude oil price is up 4.65% to US$98.80 a barrel and the Brent crude oil price is up 2% to US$96.68 a barrel. This was driven by concerns over the US-Iran ceasefire sticking.

Buy Life360 shares

Life360 Inc (ASX: 360) shares could be undervalued according to analysts at Bell Potter. This morning, the broker has retained its buy rating with a trimmed price target of $35.50. It said: “There is, therefore, some risk around the Q1 result – scheduled to be released on 12th May – and the potential of a downgrade or softening of the global MAU growth target though, on the flip side, reiteration of the guidance could be taken positively as it would show confidence in the outlook.”

Gold price rises

ASX 200 gold shares Evolution Mining Ltd (ASX: EVN) and Newmont Corporation (ASX: NEM) could have a decent finish to the week after the gold price rose slightly overnight. According to CNBC, the gold futures price is up 0.2% to US$4,785.9 an ounce. Ceasefire concerns and the release of US inflation data were behind the rise.

Buy Northern Star shares

Northern Star Resources Ltd (ASX: NST) shares could be cheap according to Bell Potter. Ahead of the release of its quarterly update and following the announcement of a share buyback, the broker has retained its buy rating and $35.00 price target. It said: “The buy-back has minimal impact on our EPS estimates going forward, however the signalling of value in the underlying business is of more importance. As noted above, we see NST as hitting the bottom of production and earnings downgrades, with some margin compression to come from the impact of fuel prices.”

The post 5 things to watch on the ASX 200 on Friday appeared first on The Motley Fool Australia.

More reading

• Here’s why Life360 shares could rise a massive 75%
• Buy, hold, sell: CSL, Magellan, and Woodside shares
• ASX 200 energy shares whipsaw amid fragile ceasefire
• Why Bendigo Bank, EBR Systems, Strickland, and Woodside shares are rising today
• March was the worst month for the gold price since June 2013. Now what?

Motley Fool contributor James Mickleboro has positions in Life360 and Woodside Energy Group Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360. The Motley Fool Australia has positions in and has recommended Life360. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.